Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib with BEAM and ASCT in Relapsed NHL/MCL
NCT00571493Phase 2Completed
- Sponsor
- University of Nebraska
- Start
- Apr 2006
- Primary completion
- Nov 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL), sponsored by University of Nebraska. Primary endpoint: Maximum Tolerated Dose of Bortezomib at 14 months. Started Apr 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
non-Hodgkin lymphoma (NHL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00571493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00571493.